Brand names: Flecarythm, Flecardia, Tambocor
Flecainide is a class Ic antiarrhythmic agent administered both orally and intravenously. It is indicated for supraventricular arrhythmias—primarily atrial fibrillation—and ventricular arrhythmias. However, it is contraindicated in patients with ischemic heart failure and, by extension, in patients with structural heart disease. In the CAST clinical trial conducted in the late 1980s, flecainide demonstrated an increase in mortality compared to the control group in patients with a history of myocardial infarction, a left ventricular ejection fraction ≤40%, and premature ventricular contractions.
Indications
- Prevention of recurrent atrial fibrillation represents the primary indication for flecainide in arrhythmia management.
- It is administered for the acute cardioversion of atrial fibrillation paroxysms, a widely utilized clinical practice commonly referred to as the "pill-in-the-pocket" approach.
- Suppression of ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).
Adverse Effects
- May induce atrioventricular (AV) block in patients with pre-existing right or left bundle branch block; thus, it must be administered with caution under close clinical monitoring.
- Induction of malignant ventricular tachyarrhythmias.
- Reduction of myocardial contractility and exacerbation of pre-existing heart failure.
- Severe bradycardia and clinical deterioration in patients with pre-existing sinus node disease who do not have an implanted pacemaker.
- Central nervous system (CNS) disorders, including confusion and agitation.
- Due to its potential to disproportionately increase ventricular rate, flecainide is typically co-administered with a beta-blocker or another AV nodal-blocking agent.
- To mitigate the risk of drug-induced life-threatening tachyarrhythmias, initiating therapy within a hospital or a medically supervised environment is highly recommended.